BECOMING A CENTER!!
New Alzheimer's Disease Core Center
Forest School of Medicine has been awarded a NIA-funded P30 Alzheimer’s Disease
Core Center (ADCC). There are 30 ADCCs nationally, and only 3 Centers in the 12-state
Southeastern region, a region with the highest per capita prevalence of
Alzheimer’s disease. The ADCC mission is to promote research and education in
Alzheimer’s disease both at Wake Forest and nationally. The Wake ADCC has a
special focus on the role played by common vascular and metabolic disorders in
promoting Alzheimer’s disease, and in developing innovative strategies for
prevention and treatment.
ADCC is led by Director Suzanne Craft, Associate Directors
Jeff Williamson and Laura Baker; Core Leaders Kaycee Sink, Mark Espeland, Stephen Rapp, Kathleen Hayden, Ryan Mott; University of
Washington affiliates Thomas Montine and Dirk Keene; and Service Leaders Akiva Mintz, Timothy Hughes, Thomas Register, and Carol Shively.
The Center will provide extensive resources
to Wake Forest investigators to support the development of research and
education in Alzheimer’s disease and related disorders. These resources
of well-characterized participants for research studies
data and biospecimen repositories including imaging, blood, cerebrospinal fluid
and cognitive/clinical data from well-characterized participants and from
non-human primate models
to a well-characterized brain bank at the University of Washington
regarding formulation of research protocols, grant applications and
publications for both human and basic research
in interdisciplinary research related to Alzheimer’s disease.
ADCC will hold an information session for the general public in Spring 2017.
Research to Make a Difference Now and in the Future
The Alzheimer’s Disease Core Center (ADCC) focuses on translational, interdisciplinary research into the pathophysiology, prevention and treatment of Alzheimer’s disease and related dementia disorders.
Our innovative research examines the changes that occur in the transition from normal aging to mild cognitive impairment and Alzheimer’s disease, and on the contribution of metabolic and vascular factors at the earliest stages of Alzheimer’s disease pathogenesis.
Beyond finding the root causes of Alzheimer’s disease, our program works with a vast network of partners to prevent the development of cognitive impairment and Alzheimer’s disease through cutting-edge clinical trials.
We are one of only a handful of Alzheimer’s disease research programs in the Southeast. Our location, in the Piedmont Triad region of North Carolina, is in an area whose population has especially high rates of diabetes, hypertension and metabolic disease.
Being located in the heart of this region provides our researchers with a unique opportunity to study individuals who have been diagnosed with specific conditions that may greatly increase their risk factor(s) for developing Alzheimer’s.
In addition, our program builds on the multidisciplinary scientific community at Wake Forest Baptist Medical Center and the J. Paul Sticht Center on Aging and Rehabilitation, one of the first centers in the world to combine comprehensive medical and psychiatric care, assessment, rehabilitation and research for aging under one roof.
Our approach brings together the latest technologies in neuroscience, neuropsychology, brain imaging and new drugs - all helping find new ways to slow brain aging. Ultimately, researchers in the ADCC hope to delay, prevent and ultimately cure Alzheimer’s disease and other dementia disorders.
Why Participate in a Clinical Trial?
There are many reasons why you may want to participate in an Alzheimer’s clinical trial.
You may want to:
- Help others, including your own family members, who may be at risk for Alzheimer’s disease
- Receive a thorough cognitive assessment and follow-up over time
- Learn more about memory and your health
- Be among the first to learn about promising interventions for the prevention and treatment of Alzheimer’s.
- Get information about local support groups and available resources
Clinical trials and observational studies allow research professionals to partner with volunteer participants to work together to discover new and effective strategies to prevent and treat Alzheimer’s.
To accomplish this goal, we need all kinds of volunteers to participate in our research studies. This includes: men and women, people from different ethnic and racial backgrounds, people who have been diagnosed with Alzheimer’s, people who have family members with memory problems, people who have certain medical conditions that may increase their risk of developing memory problems, as well as people who are totally healthy.
An intervention may work differently in one group than another. Without sufficient representation of a certain group, questions about the success of a treatment for members of that group may remain unanswered. Also, without a sufficient number of participants, a study may be delayed or produce limited or inconclusive result findings.
The purpose of this research study is to determine whether an investigational drug, azeliragon (TTP488) is safe and beneficial in delaying or altering the decline in memory...
This 18-month study investigates whether a type of insulin
improves memory when administered as a nasal spray to adults with a mild memory
impairment or early Alzheimer’s...
This 36-month study will test whether a new drug slows the progression
of memory loss associated with brain amyloid built-up, thereby delaying
Alzheimer’s-related damage in...
This 24-week study seeks to learn how adults with abnormal
insulin sensitivity and those with memory/thinking problems respond to two
This study that will evaluate an experimental drug that is
being developed for people with Alzheimer’s disease to learn if it is safe and
effective in slowing decline in...
study will identify early risk factors that predict memory decline and dementia
in adults, with or without early signs of memory impairment.